Company registration number 14923629 (England and Wales)
SKIN & BONES MEDICAL LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 JUNE 2024
PAGES FOR FILING WITH REGISTRAR
SKIN & BONES MEDICAL LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 3
SKIN & BONES MEDICAL LIMITED
BALANCE SHEET
- 1 -
2024
Notes
£
£
Fixed assets
Tangible assets
3
7,588
Current assets
Stocks
311
Cash at bank and in hand
8,689
9,000
Creditors: amounts falling due within one year
4
(24,500)
Net current liabilities
(15,500)
Net liabilities
(7,912)
Capital and reserves
Called up share capital
5
100
Profit and loss reserves
(8,012)
Total equity
(7,912)
For the financial period ended 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true
The financial statements were approved by the board of directors and authorised for issue on 24 June 2025 and are signed on its behalf by:
Dr J Lauder
Director
Company registration number 14923629 (England and Wales)
SKIN & BONES MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 JUNE 2024
- 2 -
1
Accounting policies
Company information
Skin & Bones Medical Limited is a private company limited by shares incorporated in England and Wales. The registered office is 1 Abbey Road, Whalley, Clitheroe, Lancashire, BB7 9RP.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention.
1.2
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Equipment
15% on cost
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.3
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
1.4
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
2
Employees
The average monthly number of persons (including directors) employed by the company during the period was:
2024
Number
Total
SKIN & BONES MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 JUNE 2024
- 3 -
3
Tangible fixed assets
Equipment
£
Cost
At 8 June 2023
Additions
8,927
At 30 June 2024
8,927
Depreciation and impairment
At 8 June 2023
Depreciation charged in the period
1,339
At 30 June 2024
1,339
Carrying amount
At 30 June 2024
7,588
4
Creditors: amounts falling due within one year
2024
£
Other loans
23,900
Accruals and deferred income
600
24,500
5
Called up share capital
2024
2024
Ordinary share capital
Number
£
Issued and fully paid
Ordinary shares of £1 each
100
100